International Myeloma Foundation Honors Prof. Dr. Pieter Sonneveld
With 2015 Robert A. Kyle Lifetime Achievement Award
< p > The International Myeloma Foundation (IMF) & mdash; improving the quality of life of myeloma patients while working toward prevention and a cure & mdash; will present the 13th annual Robert A. Kyle Lifetime Achievement Award to Prof. Dr. Pieter Sonneveld during a ceremony in Vienna, Austria on June 9, 2015. < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 21, 2015 Category: Hematology Source Type: news
Lowering the Cost of Cancer Drugs
The IMF this week joins in the discussion about the high cost of cancer drugs after the recent article in Mayo Clinic Proceedings about steps that can be taken to lower these costs. In this week's blog, IMF Chairman Dr. Brian Durie cites challenges in the plan laid out in Proceedings. He also presents some alternative ideas of his own as to how best to get affordable drugs into the hands of the patients that need them. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 21, 2015 Category: Hematology Source Type: news
International Myeloma Foundation Honors Prof. Dr. Pieter Sonneveld
With 2015 Robert A. Kyle Lifetime Achievement Award
The International Myeloma Foundation (IMF) — improving the quality of life of myeloma patients while working toward prevention and a cure — will present the 13th annual Robert A. Kyle Lifetime Achievement Award to Prof. Dr. Pieter Sonneveld during a ceremony in Vienna, Austria on June 9, 2015. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 21, 2015 Category: Hematology Source Type: news
ICYMI: Click here for the replay of Understanding the Immune System in Myeloma teleconference
Learn about the latest information regarding a robust immune system's effects on long-term remission by tuning in to the IMF's first Living Well with Myeloma teleconference of 2015. “Understanding the Immune System in Myeloma,” a 60-minute presentation hosted by Dr. Brian Durie, will be broadcast Thursday, Mar. 19 at 7 pm ET/4 pm PT (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 19, 2015 Category: Hematology Source Type: news
Click here to view the slides for the Understanding the Immune System in Myeloma teleconference
Learn about the latest information regarding a robust immune system's effects on long-term remission by tuning in to the IMF's first Living Well with Myeloma teleconference of 2015. “Understanding the Immune System in Myeloma,” a 60-minute presentation hosted by Dr. Brian Durie, will be broadcast Thursday, Mar. 19 at 7 pm ET/4 pm PT (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 19, 2015 Category: Hematology Source Type: news
Throughout March tweet using #DiscoverMyeloma and Takeda Oncology will donate $5 to the IMF
We are so thrilled that Millennium: The Takeda Oncology Company is a part of Myeloma Awareness Month. They are doing something very special and donating $5 to the IMF for every #DiscoverMyeloma Tweet sent this month. There are no restrictions on how many times you can Tweet using this hashtag and be counted. The goal is to spread as much awareness as possible by posting myeloma facts and starting an educational movement. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 18, 2015 Category: Hematology Source Type: news
IMF Chairs Tokyo Flow Workshop
Next Generation Flow Cytometry made its debut in Japan last weekend at a Tokyo workshop hosted by the IMF. NGF was developed with the support of the IMF's signature Black Swan Research Initiative® and is a crucial step on a pathway to a cure. Previously, the key efforts among Japanese researchers have focused on Next Generation Sequencing, but IMF Chairman Dr. Brian Durie and others demonstrated how NGF represents a vast improvement in disease detection. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 13, 2015 Category: Hematology Source Type: news
Profiles in Courage: Patients Share What It's Like to Have Myeloma
Are you a myeloma patient with a story to share? A story shared with one person can help spread awareness, but a story shared online can reach thousands. As myeloma patient Bibi Moe, diagnosed in 2003, notes, “my story can give hope to all new patients and their families.” Since her diagnosis she has been elected to the board of the Danish Multiple Myeloma Association and devotes “all my energy to working for other patients and their families here in Denmark.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 9, 2015 Category: Hematology Source Type: news
Kyprolis & #174; Meets Primary Endpoint of PFS in Head-to-Head Clinical Trial
The myeloma drug Kyprolis & #174; (carfilzomib) has met the primary endpoint of progression-free survival (PFS) when compared with Velcade & #174; (bortezomib) in patients with relapsed myeloma, according to Amgen/Onyx's recent ENDEAVOR clinical trial interim analysis. Data from this kind of “head-to-head” clinical trial comparing different myeloma treatments “help considerably… to determine the best new treatment paradigm,” IMF Chairman Dr. Brian Durie writes in his blog this week (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 6, 2015 Category: Hematology Source Type: news
Kyprolis® Meets Primary Endpoint of PFS in Head-to-Head Clinical Trial
The myeloma drug Kyprolis® (carfilzomib) has met the primary endpoint of progression-free survival (PFS) when compared with Velcade® (bortezomib) in patients with relapsed myeloma, according to Amgen/Onyx's recent ENDEAVOR clinical trial interim analysis. Data from this kind of “head-to-head” clinical trial comparing different myeloma treatments “help considerably… to determine the best new treatment paradigm,” IMF Chairman Dr. Brian Durie writes in his blog this week (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 6, 2015 Category: Hematology Source Type: news
Register now for the Living Well with Myeloma: Understanding the Immune System in Myeloma teleconference
Learn about the latest information regarding a robust immune system's effects on long-term remission by tuning in to the IMF's first Living Well with Myeloma teleconference of 2015. “Understanding the Immune System in Myeloma,” a 60-minute presentation hosted by Dr. Brian Durie, will be broadcast Thursday, Mar. 19 at 7 pm ET/4 pm PT (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 4, 2015 Category: Hematology Source Type: news
“Knowledge is Power” - Key Message of Myeloma Awareness Month
It is officially Myeloma Awareness Month (?#MAM?)!
The IMF first declared this global event in 2009, with the notion that increasing awareness of the disease could lead to early diagnosis and increased funding for researching.
This year, we are pushing the "Knowledge is power" message.
"The majority of patients have never heard of myeloma before their diagnosis," IMF President and Co-Founder Susie Novis said. "The IMF is proud to lead the charge in raising myeloma awareness across America and around the world." (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 2, 2015 Category: Hematology Source Type: news
International Myeloma Foundation Declares March “Myeloma Awareness Month”
“Knowledge is Power” Is Key Message of Month-Long Awareness Campaign
It is officially Myeloma Awareness Month (?#MAM?)!
The IMF first declared this global event in 2009, with the notion that increasing awareness of the disease could lead to early diagnosis and increased funding for researching.
This year, we are pushing the "Knowledge is power" message.
"The majority of patients have never heard of myeloma before their diagnosis," IMF President and Co-Founder Susie Novis said. "The IMF is proud to lead the charge in raising myeloma awareness across America and around the world." (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - March 2, 2015 Category: Hematology Source Type: news
Amgen Announces the European Medicines Agency Acceptance of Kyprolis & #174; (carfilzomib) Marketing Authorization Application for the Treatement of Relapsed Multiple Myeloma
Kyprolis (carfilzomib) is currently under accelerated review by the European Medicines Agency (EMA) for treatment of patients with relapsed multiple myeloma who have received at least one prior therapy!
"Achieving deep and durable responses for patients with relapsed multiple myeloma is critical towards extending the time they live without their disease progressing," said Pablo J. Cagnoni, M.D., president, Onyx Pharmaceuticals, Inc. "We look forward to working with European regulators to potentially make this important medication available." (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - February 27, 2015 Category: Hematology Source Type: news
IMF Launches New Resource Page for Ixazomib
In response to the interest in Takeda's ixazomib, an oral proteasome inhibitor, the IMF has assembled a new resource page on its website that provides a rundown on the drug's progress through clinical trials. In one of its four ongoing Phase III trials, ixazomib recently achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - February 27, 2015 Category: Hematology Source Type: news
